Venetoclax (Venclyxto®)
Dokument
Fact Sheet
Spezifizierung
Chronische Lymphatische Leukämie (CLL)
» + Obinutuzumab (Gazyvaro®)
» Erstlinie, mit Komorbidität
Stand
Oktober 2020
Dies ist die aktuell gültige Version des Dokuments
1Venetoclax + Obinutuzumab, CLL, first line, with comorbidity
1 N - number of patients2 RR - remission rate, in %3 PFS - progression-free survival in months5 OS - overall survival in months7 SAE - serious adverse events, CTCAE grade 3/411 results for control, results for new therapy12 hazard ratio for new therapy13 n. s. not significant15 n. r. – median not reached16 CIRS – Critical Illness Rating Scale